Piramal Pharma Solutions has appointed Gregory Judge as Director, Business Development, within its European team.  

The move aligns with the company’s long-term growth strategy and its continued focus on expanding strategic partnerships in high-value biologics.

In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe, a key growth area for Piramal Pharma Solutions as it scales its advanced modalities portfolio.

Greg brings extensive experience across biologics, cell and gene therapy, and next-generation therapeutic platforms. Prior to joining Piramal Pharma Solutions, he served at Thermo Fisher Scientific, where he led business development across the EMEA region and played a key role in expanding the mRNA and advanced therapies pipeline.

His earlier career includes leadership positions at Merck Life Science, Catalent Biologics, and WuXi AppTec, where he consistently delivered commercial growth, developed strategic collaborations, and supported licensing and M&A initiatives across global markets.

Greg holds a Master’s degree in Drug Discovery & Development from Drexel University College of Medicine.